Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) shares, rose in value on Friday, March 28, with the stock price down by -2.01% to the previous day’s close as strong demand from buyers drove the stock to $8.29.
Actively observing the price movement in the last trading, the stock closed the session at $8.46, falling within a range of $8.145 and $8.35. The value of beta (5-year monthly) was 1.266 whereas the PE ratio was 214.77 over 12-month period. Referring to stock’s 52-week performance, its high was $10.67, and the low was $4.71. On the whole, AUPH has fluctuated by 9.80% over the past month.
With the market capitalization of Aurinia Pharmaceuticals Inc currently standing at about $1.14 billion, investors are eagerly awaiting this quarter’s results, scheduled for on 2025-Feb-26.
Projections by analysts suggest varying estimates for the company’s quarterly revenue. Analysts have estimated the company’s revenue for the quarter at 258.58M, with a low estimate of 59.1M and a high estimate of 62.1M. Wall Street analysts also predicted that the company’s y-o-y revenues would reach 61.06M.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that AUPH’s technical picture suggests that short-term indicators denote the stock is a Hold on average. However, medium-term indicators have put the stock in the category of 50% Buy while long-term indicators on average have been pointing out that it is a 50% Buy.
The stock’s technical analysis shows that the price of AUPH currently trading nearly -0.23% and 2.47% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 50.51, while the 7-day volatility ratio is showing 2.66% which for the 30-day chart, stands at 3.80%. Furthermore, Aurinia Pharmaceuticals Inc (AUPH)’s beta value is 1.21, and its average true range (ATR) is 0.30.
A comparison of Aurinia Pharmaceuticals Inc (AUPH) with its peers suggests the former has fared considerably weaker in the market. AUPH showed an intraday change of -2.01% in last session, and over the past year, it grew by 68.15%%.
Data on historical trading for Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) indicates that the trading volumes over the past 10 days have averaged 1.08 and over the past 3 months, they’ve averaged 1.44 million. According to company’s latest data on outstanding shares, there are 140.88 million shares outstanding.
Nearly 11.08% of Aurinia Pharmaceuticals Inc’s shares belong to company insiders and institutional investors own 42.21% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 11.44 million shares as on 2025-03-14, resulting in a short ratio of 6.18. According to the data, the short interest in Aurinia Pharmaceuticals Inc (AUPH) stood at 838.00 of shares outstanding as of 2025-03-14; the number of short shares registered in 2025-02-14 reached 9.97 million. The stock has fallen by -7.68% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the AUPH stock heading into the next quarter.
